|
Study compares weekly dosing efficacies of Fosamax and Actonel.
Publication: Pharma Business Week Publication Date: 18-OCT-04 |
|
|
|
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
|
|
|
COPYRIGHT 2004 NewsRX
2004 OCT 18 - (NewsRx.com & NewsRx.net) -- Fosamax Once Weekly (alendronate sodium) increased bone mineral density (BMD) more than Actonel Once-a-Week (risedronate) with similar tolerability, according to results of the Fosamax Actonel Comparison Trial (FACT) .
This is the first U.S. head-to-head study comparing U.S. Food and Drug Administration-approved once-weekly osteoporosis treatments in postmenopausal women with osteoporosis.
In this study, Fosamax provided greater increases in BMD at all sites measured as early as 6 months, and lowered levels of biochemical markers of bone turnover further within the normal pre-menopausal range than Actonel within 3 months. Reducing and stabilizing bone turnover, which leads to increased bone density,...
Read the full article for free courtesy of your local library.
|
|
|
|
 |
| More Articles from Pharma Business Week |
Dr. Kimberley Forbes-McKean named SVP, chief technical science officer...
October 18, 2004
|
Drug discovery company names vice president finance.
October 18, 2004
|
Drug-sampling solutions provider names executive director, business de...
October 18, 2004
|
Edmund Mickunas named VP regulatory and clinical affairs.
October 18, 2004
|
Genomics company names new chairman, president.
October 18, 2004
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
